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Background: Long-term survival of high-risk neuroblastoma patients is still below 50% despite intensive multimodal
treatment. This trial aimed to address whether the addition of two topotecan-containing chemotherapy courses
compared to standard induction therapy improves event-free survival (EFS) of these patients.
Patients and methods: An open-label, multicenter, prospective randomized controlled trial was carried out at 58
hospitals in Germany and Switzerland. Patients aged 1e21 years with stage 4 neuroblastoma and patients aged 6
months to 21 years with MYCN-ampliﬁed tumors were eligible. The primary endpoint was EFS. Patients were
randomly assigned to standard induction therapy with six chemotherapy courses or to experimental induction
chemotherapy starting with two additional courses of topotecan, cyclophosphamide, and etoposide followed by
standard induction chemotherapy (eight courses in total). After induction chemotherapy, all patients received high-
dose chemotherapy with autologous hematopoietic stem cell rescue and isotretinoin for consolidation. Radiotherapy
was applied to patients with active tumors at the end of induction chemotherapy.
Results: Of 536 patients enrolled in the trial, 422 were randomly assigned to the control arm (n ¼ 211) and the
experimental arm (n ¼ 211); the median follow-up time was 3.32 years (interquartile range 1.65e5.92). At data
lock, the 3-year EFS of experimental and control patients was 34% and 32% [95% conﬁdence Interval (CI) 28% to
40% and 26% to 38%; P ¼ 0.258], respectively. Similarly, the 3-year overall survival of the patients did not differ
[54% and 48% (95% CI 46% to 62% and 40% to 56%), respectively; P ¼ 0.558]. The response to induction
chemotherapy was not different between the arms. The median number of non-fatal toxicities per patient was
higher in the experimental group while the median number of toxicities per chemotherapy course was not different.
Conclusion: While the burden for the patients was increased by prolonging the induction chemotherapy and the
toxicity, the addition of two topotecan-containing chemotherapy courses did not improve the EFS of high-risk
neuroblastoma patients and thus cannot be recommended.
Clinical Trials.gov number: NCT number 03042429.
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While long-term survival of high-risk neuroblastoma patients
has improved over recent decades, it is still below 50% to
date.1e3 Thus, there is still an urgent need for more efﬁca-
cious treatment strategies for these patients. Currently, ﬁrst-
line treatment consists of multimodal therapeutic regimens
including multi-agent induction chemotherapy, resection,Volume 31 - Issue 3 - 2020
F. Berthold et al. Annals of Oncologyand radiotherapy of the primary tumor,4,5 high-dose
chemotherapy with autologous hematopoietic stem cell
rescue,6e8 and post-consolidation treatment with oral iso-
tretinoin and/or immunotherapy, for example.9e11 The
cytostatic agents carboplatin/cisplatin, cyclophosphamide/
ifosfamide, doxorubicin, etoposide, and vincristine are
considered key drugs for neuroblastoma and have been
applied in various combinations, doses, and timings.3,12
Almost all these drugs had been selected based on in-vitro
efﬁcacy13 whereas randomized studies on drug efﬁcacy
have been exceptions. Even the length of the induction
chemotherapy to achieve long-lasting responses has
remained uncertain.14e16
Multiple clinical observations suggest that topotecan-
containing regimens are efﬁcacious in recurrent neuroblas-
toma andmay thus be prime candidates for ﬁrst-line therapy.
Treatment with high-dose cyclophosphamide, topotecan,
and vincristine achieved responses in 52% (13/25) and 19%
(11/58) of recurrent or refractory neuroblastoma, respec-
tively.17 In our experience, 61% partial and complete re-
sponses were observed in 31 relapsed patients and 72% in 11
untreated patients using topotecan, cyclophosphamide, and
etoposide.18 A randomized phase II trial showed the supe-
riority of topotecan and cyclophosphamide compared with
topotecan alone in terms of progression-free survival.19 In an
International Society of Paediatric Oncology Europe Neuro-
blastoma (SIOPEN) trial, topotecan, vincristine, and doxoru-
bicin improved the response rate of high-risk neuroblastoma
patients after COJEC induction enabling patients to proceed
to high-dose therapy.20 A Children’s Oncology Group (COG)
study demonstrated that two courses of pharmacokinetically
guided topotecan with cyclophosphamide followed by four
courses of multi-agent chemotherapy achieved tumor
response in 84% of 26 newly diagnosed neuroblastoma pa-
tients.21 Based on these ﬁndings and our previous observa-
tions,18 we aimed to assess in a largemulticenter randomized
trial whether the addition of two topotecan-containing
chemotherapy cycles improves the event-free survival (EFS)
of newly diagnosed high-risk neuroblastoma patients.
METHODS
Study design
The NB2004-HR trial was an open-label, multicenter, pro-
spective randomized controlled phase III trial carried out at
58 sites in Germany and Switzerland. It was approved by
the national regulatory authorities and by the ethical
committee of the University of Cologne and is registered at
Clinical Trials.gov (NCT number 03042429). The inclusion
criteria were (i) diagnosis of neuroblastoma according to
the International Neuroblastoma Staging System (INSS)
criteria,22 (ii) high-risk neuroblastoma as deﬁned by either
stage 4 and age 1e21 years regardless of the MYCN sta-
tus, or stage 1e3/4S with MYCN ampliﬁcation and age 6
months to 21 years, and (iii) informed consent of the
guardians anddif appropriate for age and mental devel-
opmentdalso of the patient. Exclusion criteria were (i)
participation in other clinical trials that might interfere withVolume 31 - Issue 3 - 2020the interventions or outcome assessment of the NB2004-HR
trial, (ii) pregnancy or lactation, insufﬁcient contraception
for girls of childbearing age (Pearl index exceeds 1%), (iii)
any concomitant non-protocol anticancer therapy, and (iv)
incomplete initial staging.
Central diagnostic review
Histology, MYCN assessment, and bone marrow cytology
and immunocytology were centrally reviewed. Radiological
tumor images were centrally reviewed on request for
difﬁcult cases (for details see supplementary information 1,
available at Annals of Oncology online).
Randomization
Before any treatment, patients meeting the inclusion
criteria were randomly assigned to either the standard in-
duction treatment or the experimental treatment with two
additional topotecan-containing courses. The randomization
was done blockwise and stratiﬁed according to lactate de-
hydrogenase (LDH), stage, age, and MYCN into four groups
(see supplementary information 2, available at Annals of
Oncology online).
Treatment
The standard induction chemotherapy consisted of six
alternating courses, N5 (vindesine, cisplatin, etoposide) and
N6 (vincristine, dacarbacine, ifosfamide, doxorubicin). In the
experimental arm, patients started treatment with two
courses of N8 consisting of topotecan (1.0 mg/m2 a day for
7 days as continuous infusion over 168 h), cyclophospha-
mide (100 mg/m2 a day on days 1e7 i.v. over 1 h), and
etoposide (100 mg/m2 a day on days 8e10 i.v. over 1 h).
After these two courses, six courses of N5 and N6 followed
(for the schematic see supplementary Figure S1, available at
Annals of Oncology online).
Post-induction therapy consisted of high-dose chemo-
therapy with autologous blood stem cell re-infusion,8 primary
tumor resection, radiotherapy to meta-iodobenzylguanidine
(mIBG)-avid residuals (percutaneous irradiation to the pri-
mary tumor5), 131I-mIBG-therapy to primary and metastatic
lesions,23 and oral isotretinoin (for therapeutic details see
supplementary information 3, available at Annals of Oncology
online).
Endpoints
The primary endpoint was EFS. Key secondary endpoints
were overall survival (OS), response to induction chemo-
therapy (after two courses and before high-dose chemo-
therapy), the impact of induction chemotherapy on the
extent of surgical resectability, the need for percutaneous
and/or radionuclide irradiation, and toxicity during induc-
tion chemotherapy. Adverse events were monitored
continuously, graded according to the WHO and CTCAEv3
criteria (issued 12 December 2003; http://ctep.cancer.gov/
forms. see version: CTCAEv3), and analyzed solely for the
as-treated cohort.https://doi.org/10.1016/j.annonc.2019.11.011 423
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EFS was calculated from diagnosis to the ﬁrst event which is
deﬁned as progression, recurrence, secondary malignant
disease, or death for any reason or until the last follow-up
for patients without events. OS was calculated from diag-
nosis to death for any reason or until last follow-up. The
median follow-up was calculated using the inverse Kaplane
Meier estimate.
The conﬁrmatory null hypothesis was that EFS of children
in the experimental arm does not differ from EFS in the
standard arm and was analyzed by two-sided log-rank tests
at a signiﬁcance level of 5% within the intention-to-treat
population (ITT) using a three-step adaptive group
sequential design based on the inverse normal method.24
The characteristics were deﬁned according to Pampallona
and Tsiatis25 with the option for stopping for futility,
a ¼ 5%, equally-weighted stages, shape parameter D ¼ 0,
and power of 80% if the true hazard ratio (HR) (standard
versus experimental) is 1.443. This HR corresponds to a 3-
year EFS of 45% in the standard arm and an assumed 3-
year EFS of 57.5% in the experimental arm. Analyses were
intended to be carried out after 85, 171, and 257 events
pooled over both arms. At the second interim analysis, a
data-dependent sample size recalculation was carried out
according to the conditional power principle resulting in a
ﬁnal analysis based on 286 events.
Analyses of secondary endpoints and post hoc analyses
for the as-treated per protocol (AT) and treated-as-
randomized (TAR) cohorts (Figure 1) are exploratory and
P values are given as descriptive measures to detect
meaningful effects. Deﬁnitions of the ITT, AT, and TAR co-
horts are given in the supplementary information 4 (avail-
able at Annals of Oncology online).
IBM SPSS statistical package version 25 (IBM, Ehningen,
Germany) was used for the statistical analysis. Pearson’s c2
test and Fisher’s exact test were used to compare the
proportions of two nominal variables, while medians were
compared nonparametrically by two-sided Mann-Whitney
U-tests. The frequency of grade 3 and 4 toxicities across all
induction chemotherapy courses was compared between
treatment arms using the generalized estimation equation
(GEE) approach with logit link function and AR(1) working
correlation structure to account for clustering due to or-
dered multiple observations per patients. The log-rank test
was applied to compare the survival distribution between
independent groups and univariable Cox’s proportional
hazards regression analysis was used to calculate HR. For
multivariable Cox’s regression analyses, the covariates were
ﬁtted into a stepwise model selection process (forward and
backward with Bayesian information criterion to select the
better ﬁtting model). The likelihood ratio test P value for
inclusion was 0.05 and for exclusion was >0.10. The data
lock for this analysis was 1 September 2018.RESULTS
Between 12 October 2004, and 31 December 2016, 536
patients were enrolled and eligible for random allocation.424 https://doi.org/10.1016/j.annonc.2019.11.011Of these, 111 patients (21%) were not randomly allocated
to cohorts for several reasons (Figure 1). Of the 425 patients
who were randomly assigned (79%), two ultimately did not
meet the inclusion criteria and one withdrew consent for
randomization thus resulting in 422 randomized patients for
the ﬁnal analysis. Of these, 211 were allocated to the
standard arm and 211 to the experimental arm (Table 1).
The patient cohorts of the two arms were not different with
respect to age, stage, genomic MYCN status, LDH levels
(Table 1), sex, primary or metastatic sites, and tumor
markers (supplementary Table S1, available at Annals of
Oncology online).
The median follow-up time was 3.32 years [interquartile
range (IQR) 1.65e5.92]. At the time of the data lock, 140/
211 patients in the experimental arm and 146/211 patients
in the standard arm had events. The corresponding 3-year
EFS did not differ between the arms (log-rank P ¼ 0.258)
and was 34% (95% CI 28% to 40%) in the experimental arm
and 32% (95% CI 26% to 38%) in the standard arm
(Figure 2). Similarly, no difference was observed for overall
survival (P ¼ 0.558) with a 3-year OS of 54% (95% CI 46% to
62%) in the experimental arm and 48% (95% CI 40% to 56%)
in the standard arm (Figure 2).
In a separate comparison of the AT and TAR cohorts,
neither of the compared arms showed differences regarding
EFS or OS (see supplementary Figure S2 and Table S2,
available at Annals of Oncology online). Analyses of major
clinical subgroups, deﬁned by the stratifying risk factors
LDH, MYCN ampliﬁcation, stage, age, or by response to
induction chemotherapy, also revealed no difference in EFS
and OS between the experimental and the standard arm
(see Table 2 for ITT and supplementary Table S3, available
at Annals of Oncology online, for AT and TAR). In addition,
neither the early response rates [complete response (CR),
very good partial response (VGPR), partial response (PR),
stable disease (SD), mixed response (MR), progression
(PROG)] assessed after the ﬁrst two courses of induction
chemotherapy nor those at the completion of induction
chemotherapy were different between the groups (Table 1).
Moreover, the degree of surgical resection in the experi-
mental arm was not improved compared to the standard
arm (Table 1). There were also no differences in the fraction
of patients treated with external beam irradiation or
131I-mIBG therapy as a compensatory measure to treat tu-
mor residuals after completion of induction chemotherapy
(Table 1).
Univariable analyses of potential risk factors demon-
strated an unfavorable prognostic impact only for elevated
LDH levels at diagnosis, liver metastasis, lung or pleural
metastasis, and poor response (PR/SD/MR) to induction
chemotherapy on EFS (see supplementary Table S4, avail-
able at Annals of Oncology online). In multivariable analysis
(see supplementary Table S5, available at Annals of
Oncology online), the randomization result and the treat-
ment arm had no inﬂuence on EFS or OS in the analyzed
cohorts (ITT, AT, TAR). LDH, the involvement of rare meta-
static sites (liver, lung/pleura), and tumor response before
high-dose treatment (HDT) remained independentVolume 31 - Issue 3 - 2020
Figure 1. Trial proﬁle (CONSORT diagram).
a Received alternative treatment in another country after diagnosis.
b Protocol violation: more or fewer than 6  1 courses of induction chemotherapy in the control or more or fewer than 8  1 in the experimental arm.
c Additional oral cyclophosphamide while waiting for high-dose chemotherapy.
d Dendritic cell vaccine (n ¼ 1), oral bisphosphonate (n ¼ 2), interleukin 2 (n ¼ 2), ALK inhibitor (n ¼ 3).
e More or fewer than 9  3 courses of isotretinoin.
ALK, anaplastic lymphoma kinase.
F. Berthold et al. Annals of Oncologyprognostic markers in most models. Furthermore, MYCN
ampliﬁcation was an independent prognostic marker for
poor OS but not for EFS (see supplementary Table S5,
available at Annals of Oncology online).
Non-fatal toxicities grade 3 and 4 were more frequently
observed in the experimental arm with two additional
courses of chemotherapy (P < 0.001, AT cohorts; Table 3)
but the median number of toxicities per chemotherapy
course did not differ. Grade 3/4 thrombocytopenia was
more often observed in the experimental arm while oralVolume 31 - Issue 3 - 2020mucositis occurred less frequently although a statistical
signiﬁcance was not reached (P ¼ 0.07). Patients receiving
experimental N8 courses experienced grade 3 and 4 ane-
mia, leuco/neutropenia, and thrombocytopenia more often
compared with patients receiving N5 courses (ﬁrst course)
and more anemia and thrombocytopenia but less oral
mucositis than patients receiving N6 cycles (second course;
see supplementary Tables S6 and S7, available at Annals of
Oncology online). Seven patients of the experimental arm
experienced second neoplasms but none of the standardhttps://doi.org/10.1016/j.annonc.2019.11.011 425
Table 1. Patients characteristics and treatments (ITT population)
Standard (N5/N6) n (%) Experimental
(N8 D N5/N6) n (%)
P value
Age at diagnosis (years) 211 211 0.427a
<1 2 (1) 3 (1)
1e1.5 16 (8) 25 (12)
1.5e5 153 (73) 149 (71)
5e10 33 (16) 23 (11)
10e15 5 (2) 8 (4)
15 2 (1) 3 (1)
Median (95% CI) 3.2 (2.8e3.6) 3.0 (2.7e3.3) 0.352b
Disease stage (INSS) 211 211 0.837a
Stage 1,2,3 15 (7) 12 (6)
Stages 4S or 4 <1 year 2 (1) 2 (1)
Stage 4 1 year 194 (92) 197 (93)
MYCN assessment 210 207
MYCN ampliﬁcation 87 87 0.695a
Stages 1,2,3 15 (17) 12 (14)
Stage 4S 1 (1) 1 (1)
Stage 4 <1 year 1 (1) 0 (0)
Stage 4 1 year 70 (81) 74 (85)
Time from randomization to 1st chemotherapy n ¼ 211 n ¼ 211
Median days (95% CI) 6 (5e7) 6 (6e7) 0.803b
Lengths of induction chemotherapy n ¼ 211 n ¼ 211
Median days (95% CI)d 134 (130e138) 195 (191e201) <0.001b
Response status after 2 courses 172 185 0.133a
Complete response 0 (0) 1 (1)
Very good partial response 6 (4) 6 (3)
Partial response 152 (88) 147 (80)
Stable disease 12 (7) 27 (15)
Mixed response 2 (1) 4 (2)
Progression/death before third course 3 (1) 5 (2) 0.724c
Response status before HDT 196 193 0.837a
Complete response 53 (27) 56 (29)
Very good partial response 30 (15) 29 (15)
Partial response 92 (47) 85 (44)
Stable disease 2 (1) 1 (1)
Mixed response 1 (1) 0 (0)
Progression/death 18 (9) 22 (11)
HDT 211 211 0.473c
Given 186 (88) 180 (86)
Not given 25 (12) 31 (14)
Surgery 211 211 0.884a
Complete resection 92 (44) 84 (40)
Incomplete resection 83 (39) 86 (41)
Biopsy only 16 (8) 17 (8)
No resection/biopsy 20 (9) 24 (11)
Radiotherapy (external beam) 211 211
Not given 184 (87) 184 (87)
Given 27 (13) 27 (13) 1.000c
131I-mIBG therapy 211 211
Not given 150 (71) 153 (73)
Given 61 (29) 58 (28) 0.829c
Biopsy, only biopsy material obtained, no tumor resection; CI, conﬁdence interval; complete, macroscopic complete resection with or without microscopic residuals (best
operation); HDT, high-dose treatment; 131I-mIBG, 131I-meta-iodobenzylguanidine therapy; incomplete, macroscopic incomplete resection (best operation); INSS, International
Neuroblastoma Staging System; ITT, intention to treat; MNA, MYCN ampliﬁcation; n, number of patients; VMA/HVA, vanillylmandelic acid and/or homovanillic acid in urine.
a c2 test.
b Median test.
c Fisher’s exact test.
d Length of induction chemotherapy is calculated from the ﬁrst day of the ﬁrst course to the ﬁrst day of the last course before HDT.
Annals of Oncology F. Berthold et al.therapy arm (n.s.). The diagnoses were acute myeloid leu-
kemia (n ¼ 3), renal cell carcinoma (n ¼ 2), Ewing’s sar-
coma, and B-non-Hodgkin’s lymphoma. The time interval
between the two diagnoses had a range of 12e125 months.
Two toxic deaths resulting from induction chemotherapy
were observed in each of the treatment arms (1.2% of the
AT cohorts; see supplementary Tables S8, available at
Annals of Oncology online). No death was caused by426 https://doi.org/10.1016/j.annonc.2019.11.011surgical therapy. High-dose-therapy was associated with
2.9% (standard arm) and 3.7% (experimental arm) of toxic
deaths.DISCUSSION
Our study demonstrates that intensiﬁcation of induction
therapy in high-risk neuroblastoma with the addition ofVolume 31 - Issue 3 - 2020
Figure 2. Event-free survival (A) and overall survival (B) of the intention-to-treat cohort by treatment arm.
F. Berthold et al. Annals of Oncologytwo chemotherapy courses containing topotecan, cyclo-
phosphamide, and etoposide to the NB2004-HR standard
chemotherapy did not improve patient EFS and OS but
increased the total number of toxic side-effects.
A major strength of the study is its design as a randomized,
prospective, multicenter trial. Ninety-nine percent of all high-
risk patients diagnosed in Germany during the trial period
and known to the National Children’s Cancer Tumor Registry
participated in the trial; thus selection bias for the registra-
tion of the patients can be largely excluded. The stratifying
risk factors chosen for randomization (LDH, stage, age,
MYCN) were equally distributed over the treatment arms.
The central review of tumor histology, MYCN copy number
status, bone marrow cytology, immunocytology, ambiguousTable 2. Five-year event-free survival and 5-year overall survival of the intentio
Subcohort Exp./st. 5-year event-free survival, (95% CI)
n/n Experimental Standard HR (95% CI)
Cont. vs Ex.
All 211/211 0.29 (0.21e0.37) 0.25 (0.17e0.33) 1.09 (0.87e1.3
Elevated LDH 202/201 0.25 (0.19e0.31) 0.23 (0.17e0.29) 1.04 (0.82e1.3
Normal LDH 9/10 NA NA NA
MYCN
ampliﬁcation
87/87 0.31 (0.21e0.41) 0.21 (0.11e0.31) 1.22 (0.85e1.7
No MYCN
ampliﬁcation
120/123 0.25 (0.15e0.35) 0.24 (0.14e0.34) 1.02 (0.75e1.3
Stage 4 and
age >1 year




14/17 0.52 (0.24e0.80) 0.44 (0.20e0.68) 1.62 (0.57e4.5
CR/VGPR
before HDTa
85/82 0.37 (0.25e0.49) 0.42 (0.30e0.54) 0.82 (0.55e1.2
PR/MR/SD
before HDTa
86/95 0.34 (0.24e0.44) 0.24 (0.14e0.34) 1.28 (0.90e1.8
CI, conﬁdence interval; CR, complete response; exp., experimental arm; HDT, high-dose c
drogenase (elevation deﬁned as >400 U/L <1 year, >300 U/L 1e17 years, >200 U/L >17
response; SD, stable disease; St., standard arm; VGPR, very good partial response.
a Five years measured from the time of response evaluation.
b Observations were censored at the end of the 5-year period.
Volume 31 - Issue 3 - 2020mIBG scintigraphy, and ambiguous radiodiagnostic imaging
represent other strengths of the NB2004-HR trial.
Several limitations of the study need to be highlighted.
The study was powered to detect differences between the
treatment arms but not between the subgroups. Therefore,
subgroup analyses should be regarded as descriptive only.
Of the 536 patients eligible for randomization, 21% were
not randomized. Although each individual reason may be
acceptable, the sum is high and may result in a bias.
The trial was designed to increase the 3-year EFS from
45% (NB97, HDT arm) to 57.5% but this was not achieved.
In contrast, 3-year EFS was 34% (95% CI 28% to 40%) for the
experimental arm and 32% (95% CI 26% to 38%) for the
standard arm (for details on the outcome differencesn-to-treat subcohorts by treatment group
P log
rankb
5-year overall survival, (95% CI) P log
rank
Experimental Standard HR (95% CI)
8) 0.457 0.39 (0.31e0.47) 0.36 (0.28e0.44) 1.08 (0.82e1.42) 0.582
1) 0.766 0.36 (0.28e0.44) 0.33 (0.25e0.41) 1.05 (0.80e1.38) 0.746
NA NA NA NA NA
5) 0.281 0.44 (0.32e0.56) 0.26 (0.14e0.38) 1.32 (0.87e1.99) 0.170
9) 0.912 0.35 (0.23e0.47) 0.39 (0.27e0.51) 0.94 (0.65e1.36) 0.726
6) 0.584 0.37 (0.29e0.45) 0.33 (0.25e0.41) 1.05 (0.79e1.39) 0.737
5) 0.363 0.54 (0.26e0.82) 0.44 (0.20e0.68) 1.57 (0.56e4.41) 0.396
3) 0.822 0.56 (0.44e0.68) 0.56 (0.44e0.68) 0.94 (0.59e1.52) 0.813
3) 0.170 0.47 (0.35e0.59) 0.45 (0.35e0.55) 1.12 (0.74e1.70) 0.601
hemotherapy with autologous blood stem cell transplantation; LDH, lactate dehy-
years); MR, mixed response; MYCN, oncogene MYCN; NA, not applicable; PR, partial
https://doi.org/10.1016/j.annonc.2019.11.011 427
Table 3. Non-fatal grade 3 and grade 4 toxicities after all induction chemotherapy courses per treatment arm (as-treated per protocol cohort)
Toxicity Standard arm (N [ 174) Experimental arm (N [ 164) P (3 and 4
comb.)
Ass’d Grade 3 Grade 4 Ass’d Grade 3 Grade 4
n (%) n (%) n (%) n (%)
General condition 959 87 (9) 10 (1) 1182 68 (6) 26 (2) 0.157a
Blood count
Hemoglobin 992 486 (49) 331 (33) 1250 604 (48) 424 (34) 0.759a
White blood count 1004 196 (20) 721 (72) 1255 276 (22) 873 (70) 0.547a
Granulocytes 866 89 (10) 703 (81) 1108 137 (12) 892 (81) 0.399a
Platelets 1000 165 (17) 624 (62) 1253 185 (15) 884 (71) 0.008a
Infections
Infection 992 82 (8) 4 (0.4) 1251 101 (8) 7 (1) 0.989a
Fever 1000 15 (2) 0 (0) 1248 18 (1) 0 (0) 0.927a
Oral mucositis 992 28 (3) 26 (3) 1249 25 (2) 18 (1) 0.073a
Diarrhea 991 25 (3) 12 (1) 1244 35 (3) 20 (2) 0.474a
Creatinine abnormal 999 2 (0.2) 0 (0) 1246 3 (0.2) 0 (0) NA
Bilirubin abnormal 968 11 (1) 4 (0.4) 1228 9 (1) 2 (0.2) NA
SGOT/SGPT abnormal 985 83 (8) 5 (1) 1239 107 (9) 2 (0.2) 0.400a
Abnormal LV-SF 599 0 (0) 0 (0) 739 2 (0.3) 1 (0.1) 0.836a
Ototoxicity 549 20 (4) 2 (0.4) 671 29 (4) 9 (1) NA
Peripheral neurotoxicity 977 1 (0.1) 1 (0.1) 1240 2 (0.2) 1 (0.1) 0.261a
Constipation 989 4 (0.4) 2 (0.2) 1240 2 (0.2) 2 (0.2) NA
All toxicities (n) 1006 1295 2444 1259 1603 3161






























Ass’d, number of courses assessed; CI, conﬁdence interval; comb., combined; LV-SF, left ventricular shortening fraction; NA, not applicable, P, P value comparing grade 3 and 4
combined.
a Generalized estimation equation (GEE).
b Median test.
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The most appropriate length and dose intensity of induc-
tion chemotherapy for high-risk neuroblastoma have
remained controversial in the literature. A meta-analysis of
44 trials26 indicated a correlation between increased drug
dose intensity and improved response and survival but this
ﬁnding was not conﬁrmed later when bonemarrowwas used
as ameasure ofmetastatic disease.27 In a study of the SIOPEN
group, initial failure to achieve a complete metastatic
response to rapid COJEC was overcome in half of the patients
by adding two cycles of topotecan, vincristine, and doxoru-
bicin.20 The reduction from seven to ﬁve chemotherapy
courses was not associated with changes in the response rate
of approximately 80%, as shown by a comparison of two
subsequent studies in a single institution.16 In our study, the
proportion of responses before HDT did not differ between
the arms and the poor responding subgroup did not beneﬁt
from longer induction chemotherapy.
Moreover, neither the surgical resectability nor the pro-
portion of patients who needed radiotherapy (to compen-
sate for surgical irresectability) was diminished by the
addition of two chemotherapy cycles. Thus the clinical
beneﬁt of topotecan-containing courses observed in428 https://doi.org/10.1016/j.annonc.2019.11.011refractory or recurrent disease17e20 was not validated for
newly diagnosed high-risk neuroblastoma in our trial and
within the context of therapy given. The authors cannot
offer a good explanation for the surprising result.
In conclusion, the addition of two courses of chemo-
therapy, which had been established in patients with
relapsed neuroblastoma previously, was not beneﬁcial in
newly diagnosed high-risk neuroblastoma patients in our
study. The quality of the response after two courses and
before high-dose therapy with autologous blood stem cell
transplantation, the grade of resectability of the primary
tumor, the frequency of irradiation needed for active tumor
residuals at the end of induction chemotherapy, and both EFS
and OS were not improved. By contrast, the patients had a
longer duration of induction chemotherapy and suffered
from more grade 3 and 4 toxicities. Our data, therefore,
strongly suggest that extended induction chemotherapy with
topotecan, cyclophosphamide, and etoposide cannot be
recommended for high-risk neuroblastoma patients.FUNDING
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